VSVikren Sarkar

Vikren Sarkar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vikren Sarkar has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dosimetry for proton therapy using a β -Ga 2 O 3 metal–semiconductor–metal detector with low-noise amplification

    by Hunter D Ellis, Ajayvarman Mallapillai, Jared Miller, Imteaz Rahaman, Botong Li, Vikren Sarkar, Kai Fu

    Intensity-modulated proton therapy (IMPT) employs proton radiation rather than conventional x-rays to treat cancerous tumors. This approach offers significant advantages by minimizing the radiation exposure of surrounding healthy tissue, leading to improved patient outcomes and reduced side effects compared to traditional x-ray therapy. To ensure patient safety, each treatment plan must be experimentally validated before clinical implementation. However, current dosimetry devices face limitations in performing angled beam measurements and obtaining multi-depth assessments, both of which are essential for verifying IMPT treatment plans. In this study, the performance of a β -Ga 2 O 3 -based metal–semiconductor–metal detector with a low-noise amplifier has been studied and evaluated under various proton radiation doses and energy levels delivered by a MEVION S250i proton accelerator. The detector’s performance was also compared with that of an ionization chamber. The β -Ga 2 O 3 detector exhibited a linear response with proton dose for single-spot irradiations, and its response to varying proton energies closely matched both the ion chamber data and simulated dose distributions. These findings highlight the potential of β -Ga 2 O 3 -based detectors as robust dosimetry devices for IMPT applications.

  • Open Access

    Validation of Acuros for total body irradiation at extended distance

    by Geoffrey Nelson, Vikren Sarkar, Martin Szegedi, Andrea Molineu, Arthur J. Olch, Jeremy N. Kunz, Hui Zhao, Y. Jessica Huang, Susha Pillai, Prema Rassiah

    Purpose: Standardized and accurately reported doses are essential in conventional total body irradiation (TBI), especially lung doses. This study evaluates the accuracy of the Acuros algorithm in predicting doses for extended‐distance TBI.Methods: Measurements and calculations were done with both 6 and 18 MV. Tissue Maximum Ratio (TMR), output and off axis ratios (OAR) were measured at 200 and 500 cm source to detector distance and compared to Acuros calculated values. Two end‐to‐end tests were carried out, one with an in‐house phantom (solid water and Styrofoam) with inserted ion chambers and the other was with the Imaging and Radiation Oncology Core (IROC) TBI anthropomorphic phantom equipped with TLDs. The end‐to‐end test was done for 6 and 18 MV both with and without lung blocks. The source to midplane distance for both phantoms were at 518 and 508 cm respectively. Lung blocks were placed at the phantom surface and a beam spoiler was positioned 30 cm from the surface of the phantoms as per our clinical set up.Results: The agreement between measured and calculated TMR, output and off axis ratios for both 6 and 18 MV were within 2%. Ion chamber measurements in both the Styrofoam and solid water for both energies carried out with and without lung blocks were within 2% of calculated values. TLD measured doses for both 6 and 18 MV in the IROC phantom were within 5% of calculated doses which is within the uncertainty of the TLD measurement.Conclusions: The results indicate that the clinical beam model for Acuros 16.1 commissioned at standard clinical distances is capable of calculating doses accurately at extended distances up to 500 cm.


  • Automation framework for online review of daily dose distributions using CT on Rails in proton therapy

    by Christian Dial, Geoff Nelson, Vikren Sarkar, Adam Paxton, Ryan Price, Bill Salter


  • Open Access

    Verification of surface‐guided radiation therapy (SGRT) alignment for proton breast and chest wall patients by comparison to CT‐on‐rails and kV‐2D alignment

    by Hui Zhao, Vikren Sarkar, Sara St James, Adam Paxton, Fan‐Chi Frances Su, Ryan G. Price, Christian Dial, Matthew Poppe, David Gaffney, Bill Salter

    Background: Surface‐guided radiation therapy (SGRT) systems have been widely installed and utilized on linear accelerators. However, the use of SGRT with proton therapy is still a newly developing field, and published reports are currently very limited.Purpose: To assess the clinical application and alignment agreement of SGRT with CT‐on‐rails (CTOR) and kV‐2D image‐guided radiation therapy (IGRT) for breast treatment using proton therapy.Methods: Four patients receiving breast or chest wall treatment with proton therapy were the subjects of this study. Patient #1′s IGRT modalities were a combination of kV‐2D and CTOR. CTOR was the only imaging modality for patients #2 and #3, and kV‐2D was the only imaging modality for patient #4. The patients’ respiratory motions were assessed using a 2‐min surface position recorded by the SGRT system during treatment. SGRT offsets reported after IGRT shifts were recorded for each fraction of treatment. The agreement between SGRT and either kV‐2D or CTOR was evaluated.Results: The respiratory motion amplitude was ° in rotation for all patients. The mean and maximum amplitude of SGRT offsets after application of IGRT shifts were ≤(2.6 mm, 1.6°) and (6.8 mm, 4.5°) relative to kV‐2D‐based IGRT; ≤(3.0 mm, 2.6°) and (5.0 mm, 4.7°) relative to CTOR‐based IGRT without breast tissue inflammation. For patient #3, breast inflammation was observed for the last three fractions of treatment, and the maximum SGRT offsets post CTOR shifts were up to (14.0 mm, 5.2°).Conclusions: Due to the overall agreement between SGRT and IGRT within reasonable tolerance, SGRT has the potential to serve as a valuable auxiliary IGRT tool for proton breast treatment and may improve the efficiency of proton breast treatment.


  • Open Access

    Characterization of an Onboard Transmission Detector for Efficient Linear Accelerator Output Quality Assurance

    by Jeremy Kunz, Vikren Sarkar, Adam B. Paxton, Stephen Bhagroo, Geoff Nelson, Bill Salter

    Purpose To investigate the potential to perform linear accelerator output quality assurance (QA) with the ScandiDos Delta4 Discover (Discover) onboard transmission detector. Materials and methods Using the ScandiDos Delta4 software (version 8), a conversion factor from raw signal to output was obtained via cross-calibration with an accredited dosimetry calibration laboratory (ADCL) calibrated ionization chamber for each photon energy, including flattening-filter-free (FFF) energies. With the calibration factor for 6 MV (6x) photon energy, output measurements were taken with both the Delta4 Discover and ion chamber and compared for output as a function of gantry angle and dose-rate dependence. Monitor unit (MU) linearity for 6x was measured and compared with ion chamber measurements. Additionally, the Discover was used to take output measurements, for 6x, approximately every hour throughout the course of a treatment day, and compared with ion chamber output measurements at the beginning and end of the treatment day. Results Output measurements for each photon energy were comparable with a maximum difference of -0.57% for flattened beams (6x) and 0.21% for FFF beams (10FFF). Output measurements using the Discover matched ion chamber output measurements at every dose rate within 2%, and within 1% for output as a function of gantry angle. MU linearity test agreed with ion chamber measurements with a maximum difference of 0.41%. Output measurements using the Discover showed a daily drift in output throughout the course of a treatment day of around 2% and correlated very well with ion chamber outputs measured at the beginning and end of the treatment day (within 0.2%). Conclusions The ScandiDos Delta4 Discover onboard transmission detector is able to accurately measure linear accelerator output comparable to ion chamber measurements.

  • Initial clinical evaluation of a novel combined biometric, radio-frequency identification, and surface imaging system

    by Hui Zhao, Christine Haacke, Vikren Sarkar, Adam Paxton, Y. Jessica Huang, Martin Szegedi, Ryan G. Price, Fan-Chi Frances Su, Prema Rassiah-Szegedi, Bill Salter


  • Image-guided preplanning workflow for high-dose-rate interstitial brachytherapy for gynecological malignancies

    by Y. Jessica Huang, Cristina M. DeCesaris, Vikren Sarkar, Hui Zhao, Jeremy Kunz, Geoff Nelson, Xing Li, Gita Suneja, Lindsay M. Burt, David K. Gaffney


  • Open Access

    High Fidelity, CT on Rails-based Characterization of Total Delivered Dose Variation for Conformal Head and Neck Treatment: With evaluation of adaptive replanning time-point implications

    by Haocheng Dai, Vikren Sarkar, Christian Dial, Markus D. Foote, Sarang Joshi, Bill J. Salter

    Purpose This study aims to characterize dose variations from the original plan for a cohort of head-and-neck cancer (HNC) patients using high-quality computed tomography on rails (CTOR) datasets and evaluate a predictive model for identifying patients needing re-planning. Material and methods 74 HNC patients treated on our CTOR equipped machine were evaluated in this retrospective study. Patients were treated at our facility using in-room, CTOR Image Guidance — acquiring CTOR kV fan beam CT (FBCT) images on a weekly to near-daily basis. For each patient, a particular day’s delivered treatment dose was calculated by applying the approved, planned beam set to the post image-guided alignment CT image-of-the-day. Total accumulated delivered dose distributions were calculated and compared to the planned dose distribution and differences were characterized by comparison of dose and biological response statistics. Results The majority of patients in the study saw excellent agreement between planned and delivered dose distribution in targets — the mean deviations of D95 and D98 of the planning target volumes (PTVs) of the cohort are −0.7% and −1.3%, respectively. In critical organs, we saw a +6.5% mean deviation of mean dose in parotid glands, −2.3% mean deviation of maximum dose in brainstem, and +0.7% mean deviation of maximum dose in spinal cord. 10 of 74 patients experienced nontrivial variation of delivered parotid dose which resulted in a normal tissue complication probability (NTCP) increase compared to the anticipated NTCP in the original plan, ranging from 11% to 44%. Conclusion We determined that a mid-course evaluation of dose deviation was not effective in predicting the need of re-planning for our patient cohorts. The observed non-trivial dose difference to parotid gland delivered dose suggest that even when rigorous, high quality image guidance is performed, clinically concerning variations to predicted dose delivery can still occur.

  • Open Access

    Measurements of fetal dose with Mevion S250i proton therapy system with HYPERSCAN

    by Karolyn M. Hopfensperger, Xing Li, Adam Paxton, Vikren Sarkar, Fan‐Chi Frances Su, Ryan G. Price, Bill Salter, Sara St. James

    Purpose: To characterize potential dose to the fetus for all modes of delivery (dynamic adaptive aperture, static adaptive aperture, and no adaptive aperture) for the Mevion S250i Proton Therapy System with HYPERSCAN and compare the findings with those of other available proton systems.Materials and Methods: Fetal dose measurements were performed for all three modes of dose delivery on the Mevion S250i Proton therapy system with HYPERSCAN (static aperture, dynamic aperture and uncollimated). Standard treatment plans were created in RayStation for a left‐sided brain lesion treated with a vertex field, a left lateral field, and a posterior field. Measurements were performed using WENDI and the RANDO with the detector placed at representative locations to mimic the growth and movement of the fetus at different gestational stages.Results: The fetal dose measurements varied with fetus position and the largest measured dose was 64.7 μSv per 2 Gy (RBE) fraction using the dynamic aperture. The smallest estimated fetal dose was 45.0 μSv per 2 Gy (RBE) at the base of the RANDO abdomen (47 cm from isocenter to the outer width of WENDI and 58.5 cm from the center of the WENDI detector) for the static aperture delivery. The vertex fields at all depths had larger contributions to the total dose than the other two and the dynamic aperture plans resulted in the highest dose measured for all depths.Conclusion: The reported doses are lower than reported doses using a double‐scattering system. This work suggests that avoiding vertex fields and using the static aperture will help minimize dose to the fetus.


  • Open Access

    An evaluation of the use of DirectSPR images for proton planning in the RayStation treatment planning software

    by Vikren Sarkar, Adam Paxton, Fanchi Su, Ryan Price, Geoff Nelson, Martin Szegedi, Sara St. James, Bill J. Salter

    An important source of uncertainty in proton therapy treatment planning is the assignment of stopping‐power ratio (SPR) from CT data. A commercial product is now available that creates an SPR map directly from dual‐energy CT (DECT). This paper investigates the use of this new product in proton treatment planning and compares the results to the current method of assigning SPR based on a single‐energy CT (SECT). Two tissue surrogate phantoms were CT scanned using both techniques. The SPRs derived from single‐energy CT and by DirectSPR™ were compared to measured values. SECT‐based values agreed with measurements within 4% except for low density lung and high density bone, which differed by 13% and 8%, respectively. DirectSPR™ values were within 2% of measured values for all tissues studied. Both methods were also applied to scanned containers of three types of animal tissue, and the expected range of protons of two different energies was calculated in the treatment planning system and compared to the range measured using a multi‐layer ion chamber. The average difference between range measurements and calculations based on SPR maps from dual‐ and single‐energy CT, respectively, was 0.1 mm (0.07%) versus 2.2 mm (1.5%). Finally, a phantom was created using a layer of various tissue surrogate plugs on top of a 2D ion chamber array. Dose measurements on this array were compared to predictions using both single‐ and dual‐energy CTs and SPR maps. While standard gamma pass rates for predictions based on DECT‐derived SPR maps were slightly higher than those based on single‐energy CT, the differences were generally modest for this measurement setup. This study showed that SPR maps created by the commercial product from dual‐energy CT can successfully be used in RayStation to generate proton dose distributions and that these predictions agree well with measurements.